Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Link opens in a new tab
Search content at Tel Aviv University
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Benefits of radioimmunoguided surgery for pelvic recurrence
R. Haddad
,
S. Avital
, A. Troitsa
,
J. Chen
, M. Baratz
, E. Brazovsky
, G. Gitstein
,
H. Kashtan
,
Y. Skornick
,
S. Schneebaum
*
*
Corresponding author for this work
Surgery
Clinical Departments
Tel Aviv University
Research output
:
Contribution to journal
›
Article
›
peer-review
12
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Benefits of radioimmunoguided surgery for pelvic recurrence'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Pelvic Recurrence
100%
Monoclonal Antibody
66%
Surgical Exploration
66%
Decision-making Process
33%
Operative
33%
Excision
33%
Abdomen
33%
Lymph Node Metastasis
33%
Colonoscopy
33%
Surgical Procedures
33%
Major Complications
33%
Surgeons
33%
Pelvis
33%
Occult
33%
Reoperation
33%
Minor Complications
33%
Abdominoperineal Resection
33%
Low Anterior Resection
33%
Extracolonic
33%
Pelvic Exenteration
33%
Presacral Tumor
33%
Disease Staging
33%
Exenteration
33%
Locally Recurrent Rectal Cancer
33%
Detecting Probe
33%
Pelvic Lymph Node Metastasis
33%
Urinary Leak
33%
Total Abdominal Hysterectomy
33%
Extrapelvic
33%
CC49
33%
Antibody Localization
33%
Surgeon Assessment
33%
Preoperative Assessment
33%
Bilateral Salpingo-oophorectomy
33%
Disease Extent
33%
Recurrent Pelvic Cancer
33%
Medicine and Dentistry
Recurrent Disease
100%
Pelvis
100%
Diseases
60%
Monoclonal Antibody
40%
Surgeon
40%
Lymph Node Metastasis
40%
Surgical Exploration
40%
Decision Making
20%
Surgical Technique
20%
Urinary System
20%
Colonoscopy
20%
Salpingooophorectomy
20%
Iodine 125
20%
Reoperation
20%
Tumor
20%
Rectum Cancer
20%
Preoperative Evaluation
20%
Abdominoperineal Resection
20%
Lower Anterior Resection
20%
Pelvic Exenteration
20%
Exenteration
20%
Pelvis Cancer
20%
Abdominal Hysterectomy
20%